CN Bio logoCN Bio logoCN Bio logoCN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix™ products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix™ support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix™ products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

      • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.

      • CN Bio appoints Dr Paul Brooks as Chief Executive Officer

      View all news

      Upcoming Events

      • SLAS2023

      • SOT 2023

      • WORD 2023

      • SLAS Europe 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix™ OOC Microphysiological Systems
    • Consumables
      • PhysioMimix™ multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

PhysioMimix™ organ-on-a-chip models

Single-and multi-organ-on-a-chip (OOC) models


OOC models bridge the gap between traditional cell culture, animals, and the clinic by more accurately replicating human physiology in vitro to overcome the relevance limitations of current approaches.

Explore our models

arrow down |
Single-and multi-organ-on-a-chip (OOC) models
PhysioMimix Single-organ system

Single-organ-on-a-chip


Single-organ models allow detailed investigative studies of individual organ function and modeling of specific disease states to recreate intricate human physiology in the laboratory.

Liver icon graphic

Liver-on-a-chip model

The liver is a key organ in the study of drug metabolism and safety toxicology. Understanding how a drug is processed by the liver, discovering adverse effects and informing dose setting, are crucial to drug development.

Rates of liver disease are also on the rise, driven by alcohol consumption, diabetes, obesity rates, and infection. Some remain unmet–or poorly met–therapeutically. More human-representative models are required to address these concerns.

Our Liver-on-a-chip is designed for the study of drug metabolism, toxicology, and liver diseases.

  • Easily identify liver toxicity markers, model liver disease, and study drug metabolism
  • Extended culture lifespan (> four weeks) enables the study of acute and chronic disease and drug dosing
  • Replicates liver disease with a high degree of accuracy providing a suitable system for studying signaling pathways
  • Detect phase II metabolites and drug accumulation to support clinical data interpretation
Gut icon graphic

Gut-on-a-chip model

Diet and lifestyle have a direct impact on gut health. The gut plays a complex role in maintaining health and performs a range of functions from transportation, absorption, and metabolism to playing a part in the immune response.

Understanding its physiology and pathology can inform drug pharmacology. Our Gut-on-a-chip is cultured from a mixture of epithelial and goblet cells to enable studies of drug absorption, barrier integrity, and inflammatory disease by modeling the physiology of the gut epithelium.

  • Under perfusion, a complex 3D-like morphology forms that closely models human gut physiology
  • Absorptive functions develop from increased tissue depth and greater tissue maturity
  • It exhibits a biological barrier function with permeability that is aligned to that of the human gut
  • The model expresses tight junctions and secretes mucus
Lung icon graphic

Lung-on-a-chip model

The lung is a key barrier organ, useful as a route of administration for inhaled medication. It is also susceptible to a variety of diseases caused by environmental exposure to substances. Mimicking the physiology of the human airway enables the study of drug absorption, infection, and toxicity.

Chronic respiratory diseases are some of the most common non-communicable diseases due to the presence of noxious inhaled materials around us.

We offer two human lung models (bronchial and alveolar) that capture the tissue microarchitecture of different lung areas and display their specific functions.

  • Dynamic perfusion induces shear stress and enhances microtissue formation, promoting in vivo-like functionality
  • The models reflect the complexity of lung physiology allowing translational studies of pulmonary disease and toxicity
  • The combination of an endothelial and epithelial layer of primary human cells mimics tissue-specific features
  • An air-liquid interface facilitates the effects of air-borne agents or inhaled medications to be studied

Multi-organ-on-a-chip


Multi-organ models give detailed information on organ-to-organ crosstalk, pharmacokinetics, and biodistribution. They allow drug effects on the targeted organ, as well as off-target effects on other organs, to be tested.

PhysioMimix Multi-organ system

Gut/Liver-on-a-chip model

Investigation of the ADME properties of a drug is essential during the early stages of drug development. Current approaches inadequately predict human clearance rates, miss rare or human-specific metabolites and many are incompatible with new therapeutic modalities.

As a result, drug attrition in Phase II and III clinical trials is now mainly due to a lack of clinical efficacy rather than toxicity.

We have interconnected human gut and liver models to study organ–organ crosstalk for predicting toxicity and bioavailability and modeling inflammatory disease processes.

  • Allows the combined effects of intestinal and liver metabolism to be explored
  • Organ–organ interaction and communication between the models can be used to compare oral and IV dosing regimes
  • The open system configuration allows sampling of circulating drugs, metabolites, and biomarkers to generate concentration–time profiles
  • Drug-related processes can be investigated in pharmacologically relevant concentrations
Gut/Liver icon graphic

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

+44 (0) 1223 737941

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023
  • CN Bio appoints Dr Paul Brooks as Chief Executive Officer December 19, 2022

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SLAS2023 February 25 - March 1, 2023